- Alpine’s lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 - BOSTON & SEATTLE--(BUSINESS WIRE)--Vertex ...

Your eye line is at about the same level as the brake lights of a Renault Clio, an entirely unscientific measurement that I made while dribbling along in traffic. Many people would probably say that ...

IMOLA, Italy — Even by the standards of a team that has regularly been in transition through recent Formula One history, Alpine’s past two weeks have been particularly turbulent. Within three days of ...